Development and Temporal Evaluation of Multimodal Machine Learning Models to Predict

High Inpatient Opioid Exposure

Machine Learning Models for High Inpatient Opioid Exposure

Authors and Contributions:

Swara Kale (corresponding author) (B.S.)[a] – Conceptualization; Data curation; Formal analysis;

Investigation; Methodology; Writing - original draft

Dr. Devender Singh (Ph. D)[b] – Supervision; Validation; Writing - review & editing

Dr. Eeric Truumees (MD, attending physician)[b] – Supervision; Validation; Writing - review &

editing

Dr. Matthew Geck (MD, attending physician)[b] – Supervision; Validation; Writing - review &

editing

Dr. John Stokes, MD (MD, attending physician)[b] – Supervision; Validation; Writing - review &

editing

Affiliations:

a – The University of Texas at Austin, 101 E 21st Street, Austin, Texas 78712, United States;

swarak627@gmail.com

b - Ascension Texas Spine and Scoliosis, 1004 W 32nd St #200, Austin, TX 78705, United States;

ABSTRACT

High inpatient opioid exposure is associated with increased risk of persistent opioid use. Early

identification of high-risk patients may improve opioid stewardship. We developed machine

learning models to predict high opioid exposure during hospitalization using electronic health

record data from MIMIC-IV. We conducted a retrospective study of 223,452 unique first

hospital admissions in MIMIC-IV. The outcome was high opioid exposure, defined as the top

decile among opioid-exposed admissions (MME/day ≥ 225), representing 2.65% of all

admissions. Structured early-admission features included demographics, admission

characteristics, laboratory utilization and abnormality summaries, and 24-hour procedural

indicators. Discharge-note data were incorporated using ClinicalBERT embeddings and

interpretable bigram features. Models were trained using an 80/10/10 split and evaluated with

temporal validation on the most recent 10% of admissions. Performance was assessed using

ROC-AUC and PR-AUC with 95% confidence intervals. Among structured-only models, XGBoost

achieved the best test performance (ROC-AUC 0.932 [0.924-0.940]; PR-AUC 0.223 [0.193-

0.262]). The combined structured and notes model improved precision-recall performance

(ROC-AUC 0.932 [0.920-0.943]; PR-AUC 0.276 [0.229-0.331]). Temporal evaluation showed

similar discrimination (ROC-AUC 0.929; PR-AUC 0.223). High-risk bigrams included procedural

terms such as "external fixation" and "cervical discectomy." Integration of structured and text-

derived features improved risk stratification compared to structured data alone. Interpretable

bigram signals reflected procedural complexity and orthopedic pathology, reinforcing the

clinical plausibility of model predictions. Multimodal EHR-based models accurately predict high

inpatient opioid exposure and may support targeted opioid stewardship during hospitalization.

AUTHOR SUMMARY

Opioid medications are commonly used in hospitals to treat pain, but some patients receive

very high doses, which may increase their risk of long-term opioid use, with negative side

effects such as opioid addiction. Identifying patients at risk early during their hospital stay could

help physicians make safer prescribing decisions. In this study, we used electronic health record

data from over 220,000 hospital admissions to develop computer models that estimate the

likelihood that a patient will receive high levels of opioids. We focused on information available

within the first 24 hours of admission, including basic patient characteristics, laboratory testing

patterns, and procedures. We also used information from clinical notes to capture additional

context about patient care.

We found that these models were able to accurately identify patients at higher risk, and that

combining structured data with information from clinical notes improved performance.

Importantly, the patterns identified by the models, such as certain surgical procedures, were

consistent with clinical expectations. Our findings suggest that routinely collected hospital data

can be used to support earlier identification of patients at risk for high opioid exposure. This

approach could help guide more targeted and cautious opioid prescribing practices in inpatient

settings.

INTRODUCTION

Opioid use has been a critical public health concern in the United States for the past 30

years.[1, 2] Although overdose deaths have decreased by approximately one quarter between

March 2024 and March 2025, more than 68,000 individuals died from drug overdose between

September 2024 and September 2025.[3, 4] Opioids may be obtained illicitly or through

legitimate prescriptions. Among prescription medications, opioids remain the most frequently

misused class, with more than 7.6 million prescription users transitioning to misuse annually.[5]

In 2023 alone, 13,026 individuals died from prescription opioid overdose.[6]

Opioid administration during hospitalization is common, particularly following major surgical

procedures and other high-intensity interventions.[7, 8] While short-term opioid therapy is

often clinically necessary for acute pain management, accumulating evidence indicates that

inpatient opioid exposure may increase the likelihood of persistent opioid use after discharge

and elevate the risk of long-term dependence or misuse.[9-11] Additionally, substantial

variability exists in inpatient opioid prescribing intensity across geographic regions, institutions,

and individual prescribers, even among patients with comparable clinical presentations.[12-14]

This heterogeneity suggests that factors beyond clinical necessity contribute to high-dose

exposure and that a subset of hospitalizations may experience disproportionately intense

opioid administration.

Existing efforts to mitigate opioid-related harm have largely focused on outpatient prescribing

practices, prescription drug monitoring programs, and community-level interventions.[15]

Comparatively less attention has been directed toward identifying patients at risk for extreme

opioid exposure during hospitalization, despite the hospital setting representing a critical and

potentially modifiable point of care. A predictive model capable of identifying hospitalizations

at risk for unusually high opioid dosing could enable targeted stewardship interventions, real-

time monitoring, clinical decision support, and individualized pain management strategies.

In this study, we developed and internally validated machine learning models to predict

extreme inpatient opioid exposure using electronic health record (EHR) data. Extreme exposure

was defined as the top decile of morphine milligram equivalents (MME) per hospital day among

opioid-exposed admissions. Our primary structured model incorporates demographic,

diagnostic, procedural, laboratory, and medication-derived features available early in

hospitalization to estimate the probability of unusually high opioid intensity.

We additionally evaluated a notes-only model trained on clinical documentation to determine

whether unstructured text independently contains predictive signals associated with opioid

intensity. Furthermore, we constructed a multimodal model integrating structured features

with note-derived embeddings to assess whether combining quantitative utilization data with

clinical language improved discrimination and calibration. Finally, we conducted an exploratory

bigram analysis of discharge documentation to identify specific narrative phrases enriched

among high- and low-exposure admissions, providing interpretable context for the text-derived

signals captured by the models. By systematically comparing structured, text-based, and

multimodal approaches, we aimed and were able to characterize the predictive value of diverse

data modalities for identifying high-risk inpatient opioid exposure across heterogeneous clinical

contexts.

RESULTS

Participants and Cohort Characteristics:

A total of 546,028 hospital admission records were screened, of which 223,452 unique first

admissions met eligibility criteria and were included in the final analytic cohort. Among these

admissions, 4,627 (2.65%) met criteria for high-risk opioid exposure, defined as the top decile of

daily morphine milligram equivalent (MME ≥ 225 mg/day) among opioid-exposed admissions.

Overall, 59,441 admissions (26.5%) received any opioid exposure during hospitalization. The

distribution of MME per day among opioid-exposed admissions was right-skewed, with a

median of 54.7 (IQR 19.5-122.1), 99th percentile of 643.5, and a maximum of 4,259.1.

Admissions were randomly assigned at the admission level into training (n = 178,762; 3,730

events), validation (n = 22,345; 465 events), and test (n = 22,345; 432 events) sets, with stable

outcome prevalence across splits (training: 2.09%; validation: 2.08%; test: 1.94%). Baseline

characteristics stratified by outcome status are shown in Supplementary Table 1. Compared

with non-top-decile admissions, high-risk admissions were younger (median 52 vs. 57 years, p <

0.001) and had higher laboratory utilization within 24 hours (median 36 vs. 33 labs, p < 0.001).

Medication administrations within 24 hours were substantially higher in the high-risk group

(median 49 vs. 30, p < 0.001), and surgical admissions were more frequent among high-risk

cases (70% vs. 51%, p < 0.001). Significant differences were also observed across admission

type, admission location, insurance, primary language, marital status, race, sex, and anchor

year (a de-identified calendar year assigned after date shifting to preserve patient privacy)

group) (p < 0.001).

Missing Data and Feature Processing:

The most frequently missing variables included medication event counts (53.6%) and

laboratory-derived features (29%). Indicator variables were used to capture absence of

laboratory testing within 24 hours (29.2%). After imputation and encoding, no residual missing

values remained in the analytic dataset.

Model Development and Evaluation:

Structured prediction models were developed using ridge logistic regression, random forest,

and extreme gradient boosting. Model development was performed in the training set,

hyperparameter tuning was conducted using the validation set, and final model performance

was evaluated in the independent test set. Model outputs were predicted probabilities of high-

risk opioid exposure, and classification thresholds were selected using the Youden index in the

validation set. Primary discrimination and calibration metrics are summarized in Table 1, while

threshold-dependent performance metrics are provided in Supplementary Table 2.

Table 1: Primary model performance

Dataset	Model	ROC-AUC (95% CI)	PR-AUC (95% CI)	Brier (95% CI)	Calibration intercept	Calibration slope
Validation	Ridge logistic	0.892	0.166	0.0187	—	—
Validation	Random forest	0.909	0.201	0.0181	—	—

Validation	XGBoost	0.918	0.216	0.0180	—	—
Validation	Notes-only	0.865	0.150	0.0196	—	—
Validation	Combined	0.933	0.262	0.0179	—	—
Test	Ridge logistic	0.915 (0.903-0.925)	0.185 (0.159-0.217)	0.0172 (0.0158-0.0188)	0.446	1.183
Test	Random forest	0.919 (0.909-0.928)	0.204 (0.174-0.240)	0.0169 (0.0155-0.0184)	0.083	1.094
Test	XGBoost	0.932 (0.924-0.940)	0.223 (0.193-0.262)	0.0166 (0.0152-0.0181)	0.123	1.063
Test	Notes-only	0.861 (0.840-0.881)	0.168 (0.134-0.208)	0.0189 (0.0169-0.0210)	-0.028	0.994
Test	Combined	0.932 (0.920-0.943)	0.276 (0.229-0.331)	0.0173 (0.0155-0.0191)	0.036	1.023

Model Performance: Structured-Only Models

In the validation cohort, ridge logistic regression achieved a ROC-AUC of 0.892 and PR-AUC of

0.166, random forest achieved ROC-AUC 0.909 and PR-AUC 0.201, and XGBoost achieved ROC-

AUC 0.918 and PR-AUC 0.216, demonstrating the highest discrimination among candidate

models.

In the independent test cohort, XGBoost achieved a ROC-AUC of 0.932 (95% CI: 0.924-0.940)

and PR-AUC of 0.223 (95% CI: 0.193-0.262), with a Brier score of 0.0166 and favorable

calibration (intercept 0.12; slope 1.06; ECE 0.0012) indicating minimal overfitting and

agreement between predicted and observed risk. Visual inspection of calibration curves

demonstrated close alignment across risk deciles, with no substantial miscalibration observed

in the highest-risk strata. Random forest achieved ROC-AUC 0.919 (95% CI: 0.909-0.928) and

PR-AUC 0.204, while ridge logistic regression achieved ROC-AUC 0.915 (95% CI: 0.903-0.925)

and PR-AUC 0.185. Bootstrap resampling (B = 2000) confirmed stability of performance

estimates (Table 1) (Fig 1).

Model Interpretation: SHAP Analysis

SHAP analysis of the structured XGBoost model demonstrated that early inpatient utilization

features were the strongest contributors to predicted risk of high opioid exposure (Fig 2). The

number of medication events was the most influential variable, with higher counts strongly

associated with increased predicted probability. Age also exhibited substantial contribution,

with younger age values generally associated with higher model output. Surgical status and

admission characteristics contributed moderately to risk stratification.

Notes-Only Model and Multimodal Integration:

Embeddings were available for 130,557 admissions (58.4% coverage), corresponding to 58.4%

of training admissions, 58.9% of validation admissions, and 58.4% test admissions. In the

validation subset with embeddings, the notes-only model achieved ROC-AUC 0.865 and PR-AUC

0.150. In the test subset with embeddings, the notes-only model achieved ROC-AUC 0.861 (95%

CI: 0.840-0.881) and PR-AUC 0.168 (95% CI: 0.134-0.208), with Brier score 0.0189.

We then evaluated a combined model integrating structured predictors with discharge note

embeddings within the subset with available text features. In validation, the combined model

achieved ROC-AUC 0.933 and PR-AUC 0.262. In the test subset with embeddings (n = 13,051),

the combined model achieved ROC-AUC 0.932 (95% CI: 0.920–0.943) and PR-AUC 0.276 (95%

CI: 0.229–0.331), with Brier score 0.0173 and calibration slope 1.02 (Table 1) (Fig 3). Given the

outcome prevalence of 2.65%, the baseline PR-AUC of a random classifier would be 0.0265.

Thus, the combined model achieved more than a 10-fold improvement over random precision-

recall performance, reflecting substantial enrichment of extreme opioid exposure among high-

risk predictions. However, admissions with discharge notes may represent longer or more

complex hospitalizations, and reliance on discharge documentation limits applicability to

retrospective analysis rather than prospective early prediction.

Contrastive Text Analysis:

To characterize clinically interpretable text signals, we performed a bigram-based analysis and

identified bigrams enriched among high-risk admissions, including terms related to orthopedic

and spine interventions as well as substance use history (Fig 4). A complete ranked list of

bigrams is provided in Supplementary Table 3.

Subgroup Performance:

We evaluated performance separately in surgical and non-surgical admissions to assess

heterogeneity in discrimination and calibration. In the full test cohort, outcome prevalence was

2.96% among surgical admissions (n = 11,503; 340 events) and 0.87% among non-surgical

admissions (n = 10,842; 94 events). For XGBoost, ROC-AUC was 0.919 (95% CI 0.910-0.929) with

PR-AUC 0.242 in the surgical subset, and ROC-AUC was 0.925 (95% CI 0.904-0.944) with PR-AUC

0.161 in the non-surgical subset. As precision-recall performance depends on outcome

prevalence, these values should be interpreted relative to subgroup baseline risk (0.0296 for

surgical and 0.0087 for non-surgical admissions). Thus, PR-AUC in the surgical group reflects

approximately 8-fold enrichment over random classification, whereas the non-surgical group

demonstrates nearly 18-fold enrichment despite its lower absolute PR-AUC. Calibration slopes

remained close to 1.0 in both groups.

In the subset with available discharge note embeddings, the notes-only model achieved ROC-

AUC 0.861 and PR-AUC 0.191 in surgical admissions (n = 7,768) and ROC-AUC 0.812 and PR-AUC

0.084 in non-surgical admissions (n = 5,283). In the same subset, the combined structured +

notes model achieved ROC-AUC 0.934 and PR-AUC 0.316 in surgical admissions and ROC-AUC

0.908 and PR-AUC 0.099 in non-surgical admissions (Supplementary Table 4) (Fig 5).

Temporal Validation:

To assess temporal generalizability, we performed a time-based split using admission time with

the most recent 10% of admissions reserved as a temporally held-out test cohort. Outcome

prevalence remained stable across temporal splits.

In the temporally held-out test cohort, XGBoost achieved a ROC-AUC of 0.929 and PR-AUC of

0.223, with a Brier score of 0.0161. Random forest achieved ROC-AUC 0.920 and PR-AUC 0.231,

while ridge logistic regression achieved ROC-AUC 0.900 and PR-AUC 0.171. Discrimination and

calibration in the temporal test cohort were comparable to those observed in the randomly

held-out test cohort (Table 1) (Fig 6).

DISCUSSION

In this study, we developed and internally validated machine learning models to identify

hospital admissions at risk for extreme inpatient opioid exposure. Rather than focusing solely

on discrimination metrics, our findings highlight how patterns embedded within routine

inpatient data reflect broader care complexity and resource intensity that are associated with

unusually high opioid dosing.

In clinical practice, hospitalized patients generate multimodal data streams. Structured data

quantify measurable aspects of care, such as laboratory frequency, procedural burden, and

medication administration. Unstructured notes capture physician interpretation, procedural

narratives, and contextual detail surrounding the patient's clinical course. These data

modalities represent complementary views of the same hospitalization. Our results suggest

that structured utilization patterns provide a strong foundation for identifying high-intensity

opioid exposure, while narrative documentation contributes additional context in certain

settings, particularly surgical admissions.

Extreme opioid exposure was uncommon but clinically meaningful, occurring in a small minority

of admissions. These cases were characterized by greater early laboratory utilization, higher

medication event counts, and more frequent surgical procedures. Such patterns likely reflect

more complex operative courses, trauma-related admissions, or high-acuity postoperative care

– contexts in which aggressive analgesia may be required. [16] Importantly, the model did not

rely on opioid-specific inputs alone but instead captured broader signals of clinical intensity.

This suggests that extreme dosing may be predictable from the overall trajectory of inpatient

care rather than from pain management variables in isolation.

Subgroup analyses further illustrate how context shapes predictive signals. Structured models

demonstrated stable discrimination across surgical and non-surgical admissions, indicating that

quantitative utilization features generalize across heterogeneous inpatient populations. In

contrast, the notes-only model performed more strongly in surgical contexts and less

consistently in non-surgical admissions. Surgical discharge summaries often contain detailed

procedural narratives, implant descriptions, and postoperative plans, which may encode

implicit signals of anticipated analgesic need. Medical admissions, by comparison, may contain

more templated or symptom-focused language, potentially limiting the strength of narrative-

based prediction. The improved performance observed when structured data were combined

with note embeddings suggests that quantitative measures and clinician documentation

capture partially distinct aspects of care complexity.

Bigram analysis of discharge notes supports the clinical plausibility of the learned narrative

signals. Terms enriched among high-risk admissions were predominantly related to orthopedic,

trauma, and spine procedures, such as "external fixation," "laminectomy fusion," and

"interbody fusion." These are clinical scenarios commonly associated with substantial

postoperative pain and extended analgesic requirements and have been previously identified

as procedures likely to correlate with post-operative opioid prescription.[17] Conversely,

phrases enriched among low-risk admissions reflected general review-of-systems language or

laboratory descriptors.

Temporal validation demonstrated that model performance remained stable when applied to

more recent admissions, suggesting that the predictive relationships identified were not limited

to a particular time period. Although prescribing behaviors and stewardship efforts continue to

change nationally, the model's relative stability across time supports the hypothesis that

extreme opioid exposure reflects persistent underlying drivers of care intensity rather than

transient prescribing fluctuations.[18]

From a clinical perspective, identifying admissions at risk for extreme opioid exposure has

several potential applications. Because high inpatient dosing has been associated with

downstream opioid use, persistent exposure, and increased healthcare utilization, early

identification may represent a modifiable intervention point.[19] Operationally, the model

could be deployed at the 24-hour mark following admission, once initial opioid administration

and early clinical data are available. This timepoint offers an opportunity to reassess analgesic

strategies, optimize multimodal pain management, or involve specialty consultation. Given the

observed prevalence (2.65%), risk thresholds could be selected to flag only the highest 5-10% of

predicted risk scores, thereby limiting alert burden while focusing attention on patients most

likely to experience extreme exposure. Integration into electronic clinical decision support

systems could enable automated notification to primary teams, pharmacy services, or pain

consultation programs. Importantly, predicted risk should inform clinical judgment and

proactive planning rather than mandate opioid restriction.

Additionally, opioid prescribing patterns vary across patient demographic

characteristics.[20,21] Because predictive models may inadvertently propagate underlying

practice patterns, careful evaluation across demographic subgroups is essential prior to clinical

deployment. Future work should assess subgroup discrimination, calibration, and risk threshold

performance to ensure equitable implementation and to avoid amplifying existing disparities in

opioid prescribing, particularly among female patients and individuals from racial and ethnic

minority backgrounds.

Limitations:

This study has several limitations. First, it was conducted within a single health system. External

validation is necessary to assess generalizability across institutions with different prescribing

practices and patient populations. Second, discharge note embeddings were available for only a

subset of admissions, which may introduce documentation-related selection bias. Third,

extreme opioid exposure was defined using a relative threshold within this dataset.

Recalibration may be required in settings with different prescribing distributions. Fourth,

contextual factors such as pain scores, intraoperative anesthetic regimens, and provider-level

prescribing behaviors were not explicitly modeled. Finally, the low prevalence of extreme

exposure limits positive predictive value, emphasizing that these models are best suited for risk

stratification rather than deterministic decision-making.

MATERIALS AND METHODS

Data Source and Study Setting:

We conducted a retrospective cohort study using MIMIC-IV. MIMIC-IV is a publicly available, de-

identified electronic health record (EHR) database comprising detailed clinical data from

patients admitted to Beth Israel Deaconess Medical Center, a large tertiary academic medical

center in Boston, Massachusetts.[22-24] The MIMIC-IV hospital module contains structured

clinical data from 223,452 unique patients between 2008 and 2022, including demographic

characteristics, laboratory measurements, procedures, medication administrations, and

admission-level encounter data.

Free-text clinical documentation was obtained from the MIMIC-IV-Note module, which includes

331,793 de-identified discharge summaries from 145,915 patients during the same study

period.[25] Discharge summaries were linked to structured admission-level data using the

unique hospital admission identifier.

Study Population:

All inpatient hospital admissions recorded in the MIMIC-IV hospital module during the study

period were eligible for inclusion. To avoid correlated observations from repeat

hospitalizations, only the first hospital admission per patient was included in the analysis. No

age-based exclusions were applied. For model development and evaluation, the cohort was

temporally partitioned into development and held-out test sets to enable out-of-time

validation.

Outcome Definition:

The primary outcome was extreme inpatient opioid exposure within the first 24 hours of

hospital admission. Opioid exposure was quantified as the total morphine milligram equivalents

(MME) administered during the first 24 hours following admission. MME was calculated from

published guidelines converting individual opioid doses to a common morphine-equivalent

scale using standardized equianalgesic conversion factors.[26]

Among admissions receiving any opioid during the first 24 hours (MME > 0), total 24-hour MME

values were ranked, and the 90th percentile was used to define extreme exposure. This

percentile-based threshold was calculated using the full cohort prior to model development

and applied unchanged across all data partitions.

A relative threshold was selected rather than a fixed MME cutoff for several reasons. First,

inpatient opioid prescribing can vary substantially across institutions and clinical contexts, and

no standardized definition of high-dose opioid exposure exists for acute hospitalization.[27]

Second, percentile-based approaches allow identification of patients at the extreme tail of

institutional prescribing practices while maintaining adaptability across various health systems.

In our cohort, the 90th percentile corresponded to ≥225 MME within 24 hours, representing

10% of opioid-exposed admissions and 2.65% of all hospital admissions.

The 24-hour window was selected to capture early prescribing intensity during initial

hospitalization, a clinically actionable time frame when risk stratification and intervention may

be most feasible.

Predictor Variables:

Predictor domains included demographic characteristics, laboratory utilization metrics,

procedure indicators, and non-opioid medication administration counts. Demographic variables

included age, sex, race, marital status, insurance type, primary language, admission type,

admission location, calendar year of admission, and a categorical year grouping variable.

Laboratory-related predictors included the total number of laboratory events within 24 hours,

the number of laboratories with reference ranges available, counts of abnormal laboratory

values (overall, low, and high), and the proportion of abnormal laboratory results. Procedure-

related predictors included binary indicators for major procedural categories occurring within

the first 24 hours (spine, orthopedic, neurologic, cardiac, abdominal, and vascular procedures),

a composite indicator for any procedure, total procedure count, and a surgical admission flag.

Medication-related predictors explicitly excluded opioid administrations. Variables directly

representing opioid dose or opioid administration counts were excluded from predictors. In

secondary analyses, free-text discharge summaries were used to construct text-based

predictors. As discharge summaries are authored after hospitalization and may contain post-

exposure information, text-based models were evaluated as retrospective comparators rather

than real-time early prediction tools.

Data Preprocessing and Feature Engineering:

All preprocessing steps were performed after partitioning the dataset into training, validation,

and test sets. Structured predictors were derived from data available within the first 24 hours

of admission and aggregated at the admission level.

Laboratory-related variables were treated as structurally zero when no laboratory values were

recorded during the 24-hour window. Indicator variables were created to denote admissions

with no laboratory measurements and no laboratory results with reference ranges.

For remaining numeric predictors, missing values were imputed using median imputation.

Median values were calculated using the training dataset only and applied unchanged to the

validation and test datasets.

Categorical predictors were encoded as factor variables. Missing or empty categorical values

were assigned to a separate "Unknown" category. Factor levels were defined using the training

dataset and applied consistently to validation and test datasets to ensure alignment across

partitions.

All analyses were conducted in R (version 4.4.2) and Python (version 3.12.10) using ranger,

glmnet, xgboost, and HuggingFace Transformers libraries.[28-32]

Discharge Notes Preprocessing:

Text representations were generated using a pretrained ClinicalBERT model, a domain-adapted

transformer model trained on clinical text.[33] Embeddings for validation and test sets were

generated without exposure to outcome labels and without updating model weights.

A front-back truncation strategy was applied. For each note, two tokenized segments were

generated: 1) the first 256 tokens of the note (front segment) and 2) the last 256 tokens of the

note (back segment).

Each segment was independently processed using ClinicalBERT, and the embedding

corresponding to the [CLS] token was extracted as a 768-dimensional representation. Front and

back embeddings were concatenated to produce a 1,536-dimensional vector for each

admission-level note. Resulting embedding vectors were subsequently merged with structured

admission-level predictors for downstream modeling.

Data Partitioning:

The cohort was randomly partitioned into training (80%), validation (10%), and test (10%) sets

using stratified sampling to preserve outcome prevalence across partitions. The validation set

was used for hyperparameter tuning and model selection. The test set was held out and used

exclusively for final performance evaluation. The random stratified split served as the primary

evaluation framework, while temporal validation was conducted as a secondary robustness

analysis to assess model performance under distributional shift.

Models:

Three model classes were evaluated for structured predictors: random forest, penalized logistic

regression, and gradient boosting. For text-only models, admission-level ClinicalBERT

embeddings were used as predictors in a ridge-regularized logistic regression model. Similarly,

for combined models, structured predictors and text embeddings were concatenated and

modeled using ridge-regularized logistic regression to stabilize estimation in the presence of

high-dimensional embedding features and to reduce overfitting.

Hyperparameter Tuning:

Random forest models were trained using the ranger implementation with 500 trees. Class

imbalance was addressed using inverse-prevalence class weights computed from the training

data. The regularization parameter (λ) for ridge-regularized logistic regression models was

selected using 5-fold cross-validation.

For gradient boosting models, parameters included a learning rate of 0.05, maximum tree

depth of 6, minimum child weight of 1, subsampling rate of 0.8, and column subsampling rate

of 0.8. Early stopping was applied based on validation set ROC-AUC, with training terminated if

performance did not improve for 50 consecutive rounds; the optimal number of boosting

rounds was selected accordingly.

For text-only and combined models, ridge regularization was selected via cross-validation on

the training set.

Model Evaluation:

Model performance was evaluated on the held-out test set. Discrimination was assessed using

the area under the receiver operating characteristic curve (ROC-AUC) and the area under the

precision-recall curve (PR-AUC), the latter included given the relatively low prevalence of the

outcome. 95% confidence intervals were estimated using nonparametric bootstrapping with

2,000 resamples of the test set.

Overall prediction error was quantified using the Brier score. Calibration intercept and slope

were estimated by regressing observed outcomes on the logit of predicted probabilities.

Decision curve analysis was performed for the best-performing model to evaluate net clinical

benefit across probability thresholds ranging from 0 to 0.5

Model Interpretation:

To characterize feature contributions, SHAP values were computed for the XGBoost model to

quantify the relative importance and directionality of individual predictors in relation to high

opioid exposure.[34]

Subgroup Analysis:

To evaluate model performance across clinically-distinct admission types with different

prevalences of opioid administration during hospital stays, analyses were conducted for global,

surgical, and non-surgical cohorts.

A binary surgical admission flag was derived using International Classification of Diseases (ICD)

procedure codes recorded for each hospital admission.[35, 36] Using the surgical flag, separate

models were trained and evaluated within the surgical-only and non-surgical-only cohorts. The

original global exposure threshold was retained for subgroup analyses. The same modeling

pipeline, hyperparameter selection strategy, and evaluation framework described for the global

models were applied to each subgroup. For each subgroup, discrimination, calibration, and

clinical utility metrics were reported using the same procedures applied to the full cohort.

Temporal Validation:

To evaluate model robustness to temporal dataset shift, a secondary validation was performed

using a time-based split of admissions. Hospital admissions were ordered chronologically based

on admission timestamp. The earliest 80% of admissions were assigned to a temporal training

set, the subsequent 10% to a temporal validation set, and the most recent 10% to a temporal

test set.

Imputation parameters, categorical level definitions, and any high-cardinality category handling

were derived from the temporal training set and applied unchanged to the temporal validation

and test sets to prevent information leakage.

Random forest, ridge-regularized logistic regression, and XGBoost models were retrained using

the temporal training set. Hyperparameter selection and early stopping procedures mirrored

those used in the primary random split analysis. Final performance was evaluated on the

temporal test set (latest 10% of admissions) using matching discrimination and calibration

metrics.

Contrastive Text Analysis:

To identify clinically meaningful language patterns associated with high versus low opioid

exposure, exploratory contrastive text analysis was performed on discharge summaries across

the full cohort. Discharge notes were tokenized and converted into bigrams. Tokens were

restricted to alphabetic words 3-25 characters in length, with standard English stopwords and a

curated set of clinical stopwords removed. Repeated-word bigrams were excluded, as were

bigrams occurring fewer than 100 times overall. For each retained bigram, a log-odds ratio with

Dirichlet smoothing was computed to quantify enrichment in high- versus low-opioid groups.

Acknowledgments: The authors acknowledge the PhysioNet team and the investigators who

contributed to the MIMIC-IV database.[22-25] This study used the MIMIC-IV database (version

3.1), a publicly available, de-identified clinical dataset. The authors completed the required data

use training and certification for access.

Competing Interests: The authors declare that they have no known competing financial

interests or personal relationships that could have appeared to influence the work reported in

this paper.

Funding Disclosures: The authors declare that they have no funding disclosures to report.

REFERENCES

1. Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al.

Responding to the opioid crisis in North America and beyond: recommendations of the

Stanford–Lancet Commission. The Lancet. 2022 Feb 5;399(10324):555–604.

doi:10.1016/S0140-6736(21)02252-2.

2. Office USGA. Opioid Crisis: Status of Public Health Emergency Authorities | U.S. GAO

[Internet]. [cited 2026 Feb 18]. Available from: https://www.gao.gov/products/gao-18-

685r

3. Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths

decreased? Widespread fentanyl saturation and decreased drug use among key drivers.

The Lancet Regional Health – Americas. 2025 Nov 1;51. doi:10.1016/j.lana.2025.101226

4. Centers for Disease Control and Prevention. Provisional Drug Overdose Data [Internet].

CDC. 2024. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-

data.htm

5. National Center for Drug Abuse Statistics. Prescription Drug Abuse Statistics [Internet].

NCDAS. 2024. Available from: https://drugabusestatistics.org/prescription-drug-abuse-

statistics/

6. National Institute on Drug Abuse. Drug overdose death rates [Internet]. National

Institutes of Health; 2024. Available from: https://nida.nih.gov/research-topics/trends-

statistics/overdose-death-rates

7. Horn R, Hendrix JM, Kramer J. Postoperative pain control. In: *StatPearls*. Treasure

Island (FL): StatPearls Publishing; 2025. Available from: https://www-ncbi-nlm-nih-

gov.ezproxy.lib.utexas.edu/books/NBK544298/

8. Dowell D. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United

States, 2022. MMWR Recomm Rep. 2022;71. doi:10.15585/mmwr.rr7103a1.

9. Arwi GA, Schug SA. Potential for Harm Associated with Discharge Opioids After Hospital

Stay: A Systematic Review. Drugs. 2020 Apr;80(6):573–85. doi:10.1007/s40265-020-

01294-z.

10. Hapca S, Peet L, Gibson C, Harvey A, Forget P. Persistent post-discharge opioid use and

opioid stewardship: A single-centre retrospective cohort study. Br J Pain. 2024

Dec;18(6):497–503. doi:10.1177/20494637241276106.

11. Srivastava D, Hill S, Carty S, Rockett M, Bastable R, Knaggs R, et al. Surgery and opioids:

evidence-based expert consensus guidelines on the perioperative use of opioids in the

United Kingdom. British Journal of Anaesthesia. 2021 Jun 1;126(6):1208–16.

doi:10.1016/j.bja.2021.02.030

12. Lee S, Song W, Bates DW, Urman RD, Zhang P. The recent trend of twin epidemic in the

United States: a 10-year longitudinal cohort study of co-prescriptions of opioids and

stimulants. The Lancet Regional Health - Americas. 2025 Apr 1;44:101030.

doi:10.1016/j.lana.2025.101030

13. Leventhal EL, Nathanson LA, Landry AM. Variations in Opioid Prescribing Behavior by

Physician Training. West J Emerg Med. 2019 May;20(3):428–32.

doi:10.5811/westjem.2019.3.39311.

14. Substantial Variation in Opioid Prescribing Rates among ED Providers in the Same VA

Healthcare Facility – Publication Brief [Internet]. 2019 [cited 2026 Feb 18]. Available

from:

https://www.hsrd.research.va.gov/research/citations/pubbriefs/articles.cfm?RecordID=

975

15. National Academies of Sciences, Engineering, and Medicine, Health and Medicine

Division, Board on Health Sciences Policy, Committee on Pain Management and

Regulatory Strategies to Address Prescription Opioid Abuse. Pain Management and the

Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription

Opioid Use [Internet]. Phillips JK, Ford MA, Bonnie RJ, editors. Washington (DC):

National Academies Press (US); 2017 [cited 2026 Mar 29]. doi: 10.17226/24781

16. Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and

prevention. J Pain Res. 2017 Sep 25;10:2287–98. doi:10.2147/JPR.S144066

17. Alessio-Bilowus D, Chua KP, Peahl A, Brummett CM, Gunaseelan V, Bicket MC, et al.

Epidemiology of Opioid Prescribing After Discharge From Surgical Procedures Among

Adults. JAMA Netw Open. 2024 Jun 26;7(6):e2417651.

doi:10.1001/jamanetworkopen.2024.17651

18. Luby AO, Alessio-Bilowus D, Hu HM, Brummett CM, Waljee JF, Bicket MC. Trends in

Opioid Prescribing and New Persistent Opioid Use After Surgery in the United States.

Annals of Surgery. 2025 Mar;281(3):347. doi:10.1097/SLA.0000000000006461

19. Gerlach EB, Plantz MA, Swiatek PR, Wu SA, Arpey N, Fei-Zhang D, et al. The Drivers of

Persistent Opioid Use and Its Impact on Healthcare Utilization After Elective Spine

Surgery. Global Spine Journal. 2024 Mar 1;14(2):370–9.

doi:10.1177/21925682221104731

20. Ly DP. Association of Patient Race and Ethnicity With Differences in Opioid Prescribing

by Primary Care Physicians for Older Adults With New Low Back Pain. JAMA Health

Forum. 2021 Sep 10;2(9):e212333. doi:10.1001/jamahealthforum.2021.2333

21. Yang N, Fang MC, Rambachan A. Sex Disparities in Opioid Prescription and

Administration on a Hospital Medicine Service. J Gen Intern Med. 2024

Nov;39(14):2679–88. doi:10.1007/s11606-024-08814-7

22. Johnson A, Bulgarelli L, Pollard T, Gow B, Moody B, Horng S, Celi L A, Mark R. MIMIC-IV

(version 3.1). PhysioNet. 2024. RRID:SCR_007345. Available

from: https://doi.org/10.13026/kpb9-mt58

23. Johnson AEW, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S, et al. MIMIC-IV, a

freely accessible electronic health record dataset. Scientific Data. 2023 Jan 3;10(1).

24. Goldberger AL, Amaral LA, Glass L, Hausdorff JM, Ivanov PC, et al. PhysioBank,

PhysioToolkit, and PhysioNet: components of a new research resource for complex

physiologic signals. Circulation. 2000 Jun 13;101(23):E215-20. doi:

10.1161/01.cir.101.23.e215

25. Johnson A, Pollard T, Horng S, Celi L A, Mark R. MIMIC-IV-Note: Deidentified free-text

clinical notes (version 2.2). PhysioNet. 2023. RRID:SCR_007345. doi: 10.13026/1n74-

ne17

26. Adams MCB, Sward KA, Perkins ML, Hurley RW. Standardizing research methods for

opioid dose comparison: the NIH HEAL morphine milligram equivalent calculator. Pain.

2025 Feb 3;166(8):1729-1737. doi: 10.1097/j.pain.0000000000003529

27. Cron DC, Hwang C, Hu HM, Lee JS, Dupree JM, Syrjamaki JD, Chung KC, Brummett CM,

Englesbe MJ, Waljee JF. A statewide comparison of opioid prescribing in teaching

versus nonteaching hospitals. Surgery. 2019 Apr;165(4):825-831. doi:

10.1016/j.surg.2018.10.005. Epub 2018 Nov 26.

28. R Core Team. *R: a language and environment for statistical computing*; 2025 [cited

2026 Mar 29]. Vienna: R Foundation for Statistical Computing [Internet]. Available

from: https://www.R-project.org/

29. Python Software Foundation. *Python* (version 3.12); 2025 [cited 2026 Mar 29].

[Internet]. Available from: https://www.python.org

30. Wright MN, Ziegler A. ranger: a fast implementation of random forests for high

dimensional data in C++ and R. *J Stat Softw*; 2017 Mar 31 [cited 2026 Mar 29];77(1):1–

17. [Internet]. Available from: https://doi.org/10.18637/jss.v077.i01

31. Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models

via coordinate descent. *J Stat Softw*; 2010 Feb 2 [cited 2026 Mar 29];33(1):1–22.

[Internet]. Available from: https://doi.org/10.18637/jss.v033.i01

32. Chen T, He T, Benesty M, Khotilovich V, Tang Y, Cho H, Chen K, Mitchell R, Cano I, Zhou

T, Li M, Xie J, Lin M, Geng Y, Li Y, Yuan J, Cortes D. *xgboost: extreme gradient boosting*;

2026 [cited 2026 Mar 29]. Version 3.3.0.0 [R package]. [Internet]. Available from:

https://github.com/dmlc/xgboost

33. Alsentzer E, Murphy J, Boag W, Weng WH, Jin D, Naumann T, McDermott M. Publicly

available clinical BERT embeddings. In: *Proceedings of the 2nd Clinical Natural Language*

Processing Workshop; 2019 [cited 2026 Mar 29]; Minneapolis, MN, USA. p. 72–78.

[Internet]. Available from: https://aclanthology.org/W19-1909/

34. Lundberg, S.M. and Lee, S.-I. (2017) A Unified Approach to Interpreting Model

Predictions. *Proceedings of the* 31*st International Conference on Neural Information*

Processing Systems, Long Beach, 4-9 December 2017, 4766-4777.

35. Slee VN. The International Classification of Diseases: ninth revision (ICD-9). Ann Intern

Med. 1978 Mar;88(3):424-6. doi: 10.7326/0003-4819-88-3-424.

36. World Health Organization. The ICD-10 classification of mental and behavioural

disorders. Geneva: World Health Organization; 1993. Available from:

https://www.who.int/classifications/icd/en/

FIGURE CAPTIONS

Fig 1. ROC and PR curves for ridge logistic regression, random forest, and XGBoost models (test

set)

Fig 2. SHAP Summary plot for structured XGBoost model predicting high inpatient opioid

exposure

Fig 3. ROC and PR curves for text-based models (test set)

Fig 4. Contrastive bigrams in discharge notes associated with high versus low inpatient opioid

use

Fig 5. Model discrimination (ROC-AUC, 95% CI) stratified by surgical subgroup

Fig 6. ROC and PR curves for ridge logistic regression, random forest, and XGBoost temporal

validation

Figure

Figure

Figure

Figure

Figure

Figure